Impact of the COVID-19 pandemic on the demographic and disease burden of pediatric malignant solid tumors in China : a single-center, cross-sectional study
2024 Translational Pediatrics. All rights reserved..
Background: With the development of the novel coronavirus disease 2019 (COVID-19), China implemented measures in an attempt to control the infection rate. We conducted a single-center, cross-sectional study to ascertain the impact of the COVID-19 pandemic on the equitable availability of medical resources for children diagnosed with malignant solid tumors in China.
Methods: Data on the demographics, clinical characteristics, and medical expenses of 876 patients diagnosed with neuroblastoma, rhabdomyosarcoma (RMS), Wilms tumor, hepatoblastoma (HB), Ewing sarcoma (ES), and central nervous system (CNS) tumors from 2019 to 2021, during the COVID-19 pandemic, were retrospectively collected from the National Center for Children's Health. The Pearson χ2 test and Mann-Whitney test were performed to analyze the differences among variables.
Results: Except for the regional origin of children with tumors during the epidemic, no significant differences were found in the demographic or clinical characteristics of patients at initial diagnosis. The number of patients from northern China and northeastern China who attended Beijing Children's Hospital (BCH) increased after the outbreak of COVID-19 (P=0.001). There was no significant alteration observed in the frequency of hospitalizations per individual per annum (P=0.641) or the mean expense incurred per individual per hospitalization (P=0.361). In addition, the medical insurance coverage rate of real-time settlement increased year by year.
Conclusions: After the COVID-19 outbreak, the origin of patients with solid tumor who visited BCH was concentrated in the northern region of China. COVID-19 had no impact on the other demographic factors, clinical characteristics, or economic burden of patients with pediatric malignant solid tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Translational pediatrics - 13(2024), 3 vom: 27. März, Seite 387-398 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Chiyi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
China |
|---|
| Anmerkungen: |
Date Revised 10.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/tp-23-480 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370797345 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370797345 | ||
| 003 | DE-627 | ||
| 005 | 20240410233025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/tp-23-480 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM370797345 | ||
| 035 | |a (NLM)38590381 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Chiyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of the COVID-19 pandemic on the demographic and disease burden of pediatric malignant solid tumors in China |b a single-center, cross-sectional study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2024 Translational Pediatrics. All rights reserved. | ||
| 520 | |a Background: With the development of the novel coronavirus disease 2019 (COVID-19), China implemented measures in an attempt to control the infection rate. We conducted a single-center, cross-sectional study to ascertain the impact of the COVID-19 pandemic on the equitable availability of medical resources for children diagnosed with malignant solid tumors in China | ||
| 520 | |a Methods: Data on the demographics, clinical characteristics, and medical expenses of 876 patients diagnosed with neuroblastoma, rhabdomyosarcoma (RMS), Wilms tumor, hepatoblastoma (HB), Ewing sarcoma (ES), and central nervous system (CNS) tumors from 2019 to 2021, during the COVID-19 pandemic, were retrospectively collected from the National Center for Children's Health. The Pearson χ2 test and Mann-Whitney test were performed to analyze the differences among variables | ||
| 520 | |a Results: Except for the regional origin of children with tumors during the epidemic, no significant differences were found in the demographic or clinical characteristics of patients at initial diagnosis. The number of patients from northern China and northeastern China who attended Beijing Children's Hospital (BCH) increased after the outbreak of COVID-19 (P=0.001). There was no significant alteration observed in the frequency of hospitalizations per individual per annum (P=0.641) or the mean expense incurred per individual per hospitalization (P=0.361). In addition, the medical insurance coverage rate of real-time settlement increased year by year | ||
| 520 | |a Conclusions: After the COVID-19 outbreak, the origin of patients with solid tumor who visited BCH was concentrated in the northern region of China. COVID-19 had no impact on the other demographic factors, clinical characteristics, or economic burden of patients with pediatric malignant solid tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a China | |
| 650 | 4 | |a Pediatric solid tumors | |
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a demographics | |
| 650 | 4 | |a economic burden | |
| 700 | 1 | |a Yang, Yeran |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Wenfa |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Jian, Binglin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a He, Sidou |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xisi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shihan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Peiyi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Geng |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yongli |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational pediatrics |d 2012 |g 13(2024), 3 vom: 27. März, Seite 387-398 |w (DE-627)NLM257075216 |x 2224-4344 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:3 |g day:27 |g month:03 |g pages:387-398 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/tp-23-480 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 3 |b 27 |c 03 |h 387-398 | ||